DOCKET NO.: TJU-2534/CR001.NP003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/29J

In Re Application of:

Carlo M. Croce, et al.

Application No.: 09/526,329

Filing Date: March 15, 2000 Examiner: Gary B. Nickol

TCL-1b GENE AND PROTEIN AND RELATED METHODS AND

COMPOSITIONS

EXPRESS MAIL LABEL NO: EV251284386US DATE OF DEPOSIT: Way 30, 2003

Confirmation No.: 9316

Group Art Unit: 1642

EA52758438PNZ

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is
being filed either within three months of the filing date of the above-identified
application, within three months of the date of entry into the national stage of
the above identified application as set forth in § 1.491, before the mailing date
of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of reques					
	continued examination under § 1.114, no additional fee is required.					
	In accordance with § 1.129(a), this Information Disclosure Statement is being					
	filed in connection with the first or second After Final Submission,					
	therefore:					
	Certification in Accordance with § 1.97(e) is attached; or					
	The fee of $$180.00$ as set forth in § 1.17(p) is attached.					
\boxtimes	In accordance with § 1.97(c), this Information Disclosure Statement is being					
	filed after the period set forth in § 1.97(b) above but before the mailing date of					
	either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or					
	before an action that otherwise closes prosecution in the application, therefore:					
	Certification in Accordance with § 1.97(e) is attached;					
	or					
	The fee of \$180.00 as set forth in § 1.17(p) is attached.					
	In accordance with § 1.97(d), this Information Disclosure Statement is being					
	filed after the mailing date of either a Final Action under § 1.113 or a Notice					
	of Allowance under § 1.311 but before, or simultaneously with, the payment					
	of the Issue Fee, therefore included are: Certification in Accordance with §					
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).					
\boxtimes	Copies of each of the references listed on the attached Form PTO-1449 are					
	enclosed herewith.					

DOCKET NO.: TJU-2534/CR001.NP003-3-

PATENT

Copies of references listed on the attached Form PTO-1449 are enclosed						
herew	vith					
EXCEPT THAT:						
	In view of the voluminous nature of references [list as appropriate],					
	and the likelihood that these references are available to the Examiner,					
	copies are not enclosed herewith.					
	In accordance with § 1.98(d), copies of the following references listed					
	on the attached Form PTO-1449 are not enclosed herewith because					
	they were previously cited by or submitted to the U.S. Patent and					
	Trademark Office in patent application(s) for which a claim for priority					
	under 35 U.S.C.§ 120 have been made in the instant application:					
	Copies of references [list as appropriate] listed on the attached Form					
	PTO-1449 were previously cited by or submitted to the Patent and					
	Trademark Office in prior Application No. , filed .					
	If any of the foregoing publications are not available to the					
	Examiner, Applicant will endeavor to supply copies at the					
	Examiner's request.					

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the EPO Supplementary Partial European Search Report dated March 25, 2003 (number 1 on the PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Date: May 30, 2003

Tara L. Rachinsky Registration No. 47,875

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2003 WW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

Carlo M. Croce

Confirmation No.: 9316

Application No.: 09/526,329

Group Art Unit: 1642

Filing Date: March 15, 2000

Examiner: Gary B. Nickol

For: TCL-1b GENE AND PROTEIN AND RELATED METHODS AND

COMPOSITIONS

EXPRESS MAIL LABEL NO: EV251284386US DATE OF DEPOSIT: May 30, 2003

PLACE EXPRESS MAIL LABEL PEEL OFF STICKER HERE

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

\boxtimes	Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
	No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after

making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: May 30, 2003

Tara L. Rachinsky

Registration No. 47,875

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW



Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Docket No. TJU-2534/ CR001.Np003

Application No. 09/526,329

Applicant

Carlo M. Croce, et al.

Filing Date March 15, 2000 Group 1642

U. S. PATENT DOCUMENTS

Examiner	Document	_			
Initial	No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner					Translation	
Initial		Document No.	Date	Country	YES	NO
	6	WO 94/24308	10/27/94	PCT		
	7	WO 96/13514	05/09/96	PCT		
EVAMINED				DATE CONCE		



		Docket No. TJU-2534/ CR001.Np003	Application No. 09/526,329		
(Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Carlo M. Croce, et al.			
	epartment of Commerce t and Trademark Office	Filing Date March 15, 2000	Group 1642		
ОТНЕ	R DOCUMENTS (Including Author	, Title, Date, Pertinent	Pages, Etc.)		
1	Copy of the EPO Supplementary Partial European Search Report dated March 25, 2003 (EP 00 91 4959)				
2	Pekarsky, Y., et al., "Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1999, 96(6), XP-002235943, 2949-2951				
3	Pekarsky, Y., et al., "Homo sapiens T-cell leukemia/lymphoma 1B (TCL1B) mRNA, complete cds," Accession No. AF110466, Version 4, March 3, 2000 (created March 11, 1999), XP002235944, Database EMBL 'Online!, 1 page				
4	Pekarsky, Y., et al., "Homo sapiens T-cell leukemia/lymphoma 1B (TCL1B) gene, complete cds," <i>Accession No. AF110465</i> , Version 4, March 3, 2000 (created March 11, 1999), XP-002235945, <i>Database EMBL 'Online!</i> , 2 pages				
5	5 Sakashita, A., et al., "Amplification of the TCL1 flanking region at 14q32.1 with r TCL1 gene transcription in a patient with peripheral T cell lymphoma," <i>Leukemia</i> , 1998, 12, 970-971				
EXAMINER		DATE CONSIDERED)		